Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment.

Selnes P, Aarsland D, Bjørnerud A, Gjerstad L, Wallin A, Hessen E, Reinvang I, Grambaite R, Auning E, Kjærvik VK, Due-Tønnessen P, Stenset V, Fladby T.

J Alzheimers Dis. 2013;33(3):723-36. doi: 10.3233/JAD-2012-121603.

PMID:
23186987
2.

The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.

Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO.

J Intern Med. 2014 Apr;275(4):418-27. doi: 10.1111/joim.12164. Epub 2013 Dec 11.

3.

Network Disruption and Cerebrospinal Fluid Amyloid-Beta and Phospho-Tau Levels in Mild Cognitive Impairment.

Canuet L, Pusil S, López ME, Bajo R, Pineda-Pardo JÁ, Cuesta P, Gálvez G, Gaztelu JM, Lourido D, García-Ribas G, Maestú F.

J Neurosci. 2015 Jul 15;35(28):10325-30. doi: 10.1523/JNEUROSCI.0704-15.2015.

4.

Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.

Egli SC, Hirni DI, Taylor KI, Berres M, Regeniter A, Gass A, Monsch AU, Sollberger M.

J Alzheimers Dis. 2015;44(2):625-33. doi: 10.3233/JAD-141716.

PMID:
25322924
5.

Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.

Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, Shacklett A, Parmpi P, Shaw L, Trojanowski JQ, Davatzikos C; Alzheimer's Neuroimaging Initiative.

Neuroimage Clin. 2013 Nov 28;4:164-73. doi: 10.1016/j.nicl.2013.11.010. eCollection 2014.

6.

Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.

Susanto TA, Pua EP, Zhou J; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;45(1):253-68. doi: 10.3233/JAD-142451.

PMID:
25524955
7.

New MRI markers for Alzheimer's disease: a meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements.

Clerx L, Visser PJ, Verhey F, Aalten P.

J Alzheimers Dis. 2012;29(2):405-29. doi: 10.3233/JAD-2011-110797.

PMID:
22330833
8.

Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease.

Bertens D, Knol DL, Scheltens P, Visser PJ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 May;11(5):511-22. doi: 10.1016/j.jalz.2014.05.1754. Epub 2014 Aug 20.

9.

T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.

Haris M, Yadav SK, Rizwan A, Singh A, Cai K, Kaura D, Wang E, Davatzikos C, Trojanowski JQ, Melhem ER, Marincola FM, Borthakur A.

Neuroimage Clin. 2015 Feb 26;7:598-604. doi: 10.1016/j.nicl.2015.02.016. eCollection 2015.

10.

Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.

Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T.

Parkinsonism Relat Disord. 2015 Jul;21(7):758-64. doi: 10.1016/j.parkreldis.2015.04.027. Epub 2015 May 2.

PMID:
25971633
11.

Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.

van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2017 Dec 1;74(12):1481-1491. doi: 10.1001/jamaneurol.2017.2712.

PMID:
29049480
12.

Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease.

Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, Rich K, Kim BC, Mehta P, Zinkowski R, Pratico D, Wallin A, Zetterberg H, Tsui WH, Rusinek H, Blennow K, de Leon MJ.

J Alzheimers Dis. 2009;16(2):351-62. doi: 10.3233/JAD-2009-0968.

13.

Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers.

Lehmann M, Koedam EL, Barnes J, Bartlett JW, Barkhof F, Wattjes MP, Schott JM, Scheltens P, Fox NC; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2013 Jan;34(1):73-82. doi: 10.1016/j.neurobiolaging.2012.03.010. Epub 2012 Apr 18.

PMID:
22516280
14.

CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.

Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Brewer JB, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

J Neurosci. 2010 Feb 10;30(6):2088-101. doi: 10.1523/JNEUROSCI.3785-09.2010.

15.

Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.

van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F, Blankenstein MA, Scheltens P.

J Alzheimers Dis. 2012;29(2):319-27. doi: 10.3233/JAD-2011-111694.

PMID:
22233766
16.

Predicting MCI outcome with clinically available MRI and CSF biomarkers.

Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2011 Oct 25;77(17):1619-28. doi: 10.1212/WNL.0b013e3182343314. Epub 2011 Oct 12.

17.

Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.

Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.

J Alzheimers Dis. 2015;44(2):525-39. doi: 10.3233/JAD-141725.

PMID:
25391385
18.

Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment.

Malpas CB, Saling MM, Velakoulis D, Desmond P, O'Brien TJ; Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;47(4):965-75. doi: 10.3233/JAD-142643.

PMID:
26401775
19.

CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease.

Bendlin BB, Carlsson CM, Johnson SC, Zetterberg H, Blennow K, Willette AA, Okonkwo OC, Sodhi A, Ries ML, Birdsill AC, Alexander AL, Rowley HA, Puglielli L, Asthana S, Sager MA.

PLoS One. 2012;7(6):e37720. doi: 10.1371/journal.pone.0037720. Epub 2012 Jun 6.

20.

CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.

Bouwman FH, Schoonenboom SN, van der Flier WM, van Elk EJ, Kok A, Barkhof F, Blankenstein MA, Scheltens P.

Neurobiol Aging. 2007 Jul;28(7):1070-4. Epub 2006 Jun 19.

PMID:
16782233

Supplemental Content

Support Center